Disparate effects of adalimumab and fumaric acid esters on cardiovascular risk factors in psoriasis patients: Results from a prospective, randomized, observer-blinded head-to-head trial

Psoriasis

A phase 4, randomised, head-to-head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate-to-severe plaque psoriasis (CHANGE)

J Eur Acad Dermatol Venereol.

Pinter A, Hoffmann M, Reich K, Augustin M, Kaplan K, Gudjónsdóttir SD, Delvin T, Mrowietz U, CHANGE investigator group.

doi: 10.1111/jdv.16932.

Psoriasis

Direct Comparison of Risankizumab and Fumaric Acid Esters in Systemic-Therapy-Naive Patients With Moderate to Severe Plaque Psoriasis: A Randomized Controlled Trial

Br J Dermatol

Thaçi D, Eyerich K, Pinter A, Sebastian M, Unnebrink K, Rubant S, Williams DA, Weisenseel P

doi: 10.1111/bjd.20481

Psoriasis

The risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor-α inhibitors versus phototherapy: An observational cohort study

J Am Acad Dermatol.

Wu JJ, Sundaram M, Cloutier M, Gauthier-Loiselle M, Guérin A, Singh R, Ganguli A

doi: 10.1016/

Psoriasis

Efficacy and safety of fumaric acid esters in young patients aged 10 to 17 years with moderate-to-severe plaque psoriasis - A randomised, double-blinded, placebo-controlled trial

Br J Dermatol

Hamm H, Wilsmann-Theis D, Tsianakas A, Gambichler T, Taipale K, Lauterbach J, Freudensprung U, Makepeace C, KIFUderm study investigators.

doi: 10.1111/bjd.19747

Psoriasis

A Head-to-Head Comparison of Ixekizumab Versus Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis: 24-Week Efficacy and Safety Results from a Randomised, Double-Blinded Trial

Br J Dermatol.

Blauvelt A, Leonardi C, Elewski B, Crowley JJ, Guenther LC, Gooderham M, Langley RG, Vender R, Pinter A, Griffiths CEM, Tada Y, Elmaraghy H, Lima RG, Gallo G, Renda L, Burge R, Park SY, Zhu B, Papp K, IXORA-R Study Group

doi: 10.1111/bjd.19509.

Psoriasis

Patient-reported outcomes with risankizumab versus fumaric acid esters in systemic therapy-naïve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial

J Eur Acad Dermatol Venereol

Thaçi D, Soliman AM, Eyerich K, Pinter A, Sebastian M, Unnebrink K, Rubant S, DA Williams, Weisenseel P

doi: 10.1111/jdv.17109

Psoriasis

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study

J Am Acad Dermatol.

Bagel J, Duffin KC, Moore A, Ferris LK, Siu K, Steadman J, Kianifard F, Nyirady J, Lebwohl M

doi: 10.1016/j.jaad.2017.05.033.

Psoriasis

Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial

J Eur Acad Dermatol Venereol.

Papp KA, Blauvelt A, Kimball AB, Han C, Randazzo B, Wasfi Y, Shen YK, Li S, Griffiths CEM

doi: 10.1111/jdv.14910.

Psoriasis

Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naïve to systemic treatment: Results from a randomised, active comparator-controlled phase 3b trial (POLARIS)

Br J Dermatol.

Thaҫi D, Pinter A, Sebastian M, Termeer C, Sticherling M, Gerdes S, Wegner S, Krampe S, Bartz H, Rausch C, Mensch A, Eyerich K

doi: 10.1111/bjd.18696.

Related content

A phase 4, randomised, head-to-head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate-to-severe plaque psoriasis (CHANGE)

Direct Comparison of Risankizumab and Fumaric Acid Esters in Systemic-Therapy-Naive Patients With Moderate to Severe Plaque Psoriasis: A Randomized Controlled Trial

The risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor-α inhibitors versus phototherapy: An observational cohort study

Efficacy and safety of fumaric acid esters in young patients aged 10 to 17 years with moderate-to-severe plaque psoriasis - A randomised, double-blinded, placebo-controlled trial

A Head-to-Head Comparison of Ixekizumab Versus Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis: 24-Week Efficacy and Safety Results from a Randomised, Double-Blinded Trial

Patient-reported outcomes with risankizumab versus fumaric acid esters in systemic therapy-naïve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study

Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial

Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naïve to systemic treatment: Results from a randomised, active comparator-controlled phase 3b trial (POLARIS)